Literature DB >> 28546503

Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased α5β1 integrin expression.

Prajna Guha1, Marissa Cunetta1, Ponnandai Somasundar1, N Joseph Espat1, Richard P Junghans1, Steven C Katz2,3.   

Abstract

Chimeric antigen receptor expressing T cells (CAR-T) are a promising form of immunotherapy, but the influence of age-related immune changes on CAR-T production remains poorly understood. We showed that CAR-T cells from geriatric donors (gCAR-T) are functionally impaired relative to CAR-T from younger donors (yCAR-T). Higher transduction efficiencies and improved cell expansion were observed in yCAR-T cells compared with gCAR-T. yCAR-T demonstrated significantly increased levels of proliferation and signaling activation of phosphorylated (p)Erk, pAkt, pStat3, and pStat5. Furthermore, yCAR-T contained higher proportions of CD4 and CD8 effector memory (EM) cells, which are known to have enhanced cytolytic capabilities. Accordingly, yCAR-T demonstrated higher levels of tumor antigen-specific cytotoxicity compared with gCAR-T. Enhanced tumor killing by yCAR-T correlated with increased levels of perforin and granzyme B. yCAR-T had increased α5β1 integrin expression, a known mediator of retroviral transduction. We found that treatment with M-CSF or TGF-β1 rescued the impaired transduction efficiency of the gCAR-T by increasing the α5β1 integrin expression. Neutralization of α5β1 confirmed that this integrin was indispensable for CAR expression. Our study suggests that the increase of α5β1 integrin expression levels enhances CAR expression and thereby improves tumor killing by gCAR-T. © Society for Leukocyte Biology.

Entities:  

Keywords:  M-CSF; TGF-β1; retronectin; transduction

Mesh:

Substances:

Year:  2017        PMID: 28546503      PMCID: PMC6608072          DOI: 10.1189/jlb.5HI0716-322RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  14 in total

1.  CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.

Authors:  Isabelle Magalhaes; Ingrid Kalland; James N Kochenderfer; Anders Österborg; Michael Uhlin; Jonas Mattsson
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

2.  HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases.

Authors:  Steven C Katz; John Hardaway; Ethan Prince; Prajna Guha; Marissa Cunetta; Ashley Moody; Li Juan Wang; Vincent Armenio; N Joseph Espat; Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2019-06-03       Impact factor: 5.987

3.  Lower T cell inhibitory receptor level in mononuclear cells from cord blood compared with peripheral blood.

Authors:  Ying Lin; Jinrong Lin; Jingying Huang; Youchun Chen; Jiaxiong Tan; Yangqiu Li; Shaohua Chen
Journal:  Stem Cell Investig       Date:  2019-10-21

Review 4.  Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Authors:  Pei-Hua Lu; Kai-Yan Liu; Xing-Yu Cao; Jing-Jing Li
Journal:  Int J Hematol       Date:  2022-06-23       Impact factor: 2.319

Review 5.  T cell senescence and CAR-T cell exhaustion in hematological malignancies.

Authors:  Dimitri Kasakovski; Ling Xu; Yangqiu Li
Journal:  J Hematol Oncol       Date:  2018-07-04       Impact factor: 17.388

Review 6.  Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.

Authors:  Xinjie Xu; Shengkang Huang; Xinyi Xiao; Qihang Sun; Xiaoqian Liang; Sifei Chen; Zijing Zhao; Zhaochang Huo; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

7.  ITGA5 is a prognostic biomarker and correlated with immune infiltration in gastrointestinal tumors.

Authors:  Hai Zhu; Gang Wang; Haixing Zhu; Aman Xu
Journal:  BMC Cancer       Date:  2021-03-12       Impact factor: 4.430

8.  Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.

Authors:  Yimei Que; Menglei Xu; Yanjie Xu; Varlene Daniela Fernandes Almeida; Li Zhu; Zhiqiong Wang; Ying Wang; Xian Liu; Lijun Jiang; Di Wang; Chunrui Li; Jianfeng Zhou
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

Review 9.  T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.

Authors:  Palak H Mehta; Salvatore Fiorenza; Rachel M Koldej; Anthony Jaworowski; David S Ritchie; Kylie M Quinn
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

Review 10.  Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.

Authors:  Xinjie Xu; Qihang Sun; Xiaoqian Liang; Zitong Chen; Xiaoli Zhang; Xuan Zhou; Meifang Li; Huilin Tu; Yu Liu; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2019-11-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.